Palisade Bio (PALI) Share-based Compensation (2010 - 2026)
Palisade Bio (PALI) reported Share-based Compensation of $4.3 million for Q1 2026, up 7428.07% year-over-year from $57000.0 in Q1 2025, and up 15.29% on a QoQ basis from $3.7 million in Q4 2025.
Palisade Bio (PALI) has 17 years of Share-based Compensation data on file, last reported at $4.3 million in Q1 2026.
- Quarterly Share-based Compensation rose 7428.07% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (up 5014.46% YoY) and the FY2025 annual result came in at $3.9 million, up 2806.67% from the prior year.
- Share-based Compensation improved to $4.3 million in Q1 2026 per PALI's latest filing, from $3.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $4.3 million in Q1 2026 and bottomed at -$440000.0 in Q4 2024.
- The 5-year median for Share-based Compensation is $125000.0 (2024), against an average of $595058.8.
- The widest annual swing landed in 2024, when Share-based Compensation slumped 172.61%; it then jumped 7428.07% in 2026.
- Tracing PALI's Share-based Compensation over 5 years: stood at $86000.0 in 2022, then surged by 604.65% to $606000.0 in 2023, then tumbled by 172.61% to -$440000.0 in 2024, then jumped by 945.91% to $3.7 million in 2025, then climbed by 15.29% to $4.3 million in 2026.
- Per Business Quant, the three latest PALI Share-based Compensation figures stand at $4.3 million (Q1 2026), $3.7 million (Q4 2025), and $85000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | 4.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.29 Mn |
| Mar 31, 2026 | 4.29 Mn |
| Dec 31, 2025 | 3.72 Mn |
| Dec 31, 2025 | 3.72 Mn |
| Sep 30, 2025 | 85,000.00 |
| Sep 30, 2025 | 85,000.00 |
| Jun 30, 2025 | 60,000.00 |
| Jun 30, 2025 | 60,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Dec 31, 2024 | -440,000.00 |
| Dec 31, 2024 | -440,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 125,000.00 |
| Jun 30, 2024 | 125,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Dec 31, 2023 | 606,000.00 |
| Dec 31, 2023 | 606,000.00 |
| Sep 30, 2023 | 192,000.00 |
| Sep 30, 2023 | 192,000.00 |
| Jun 30, 2023 | 144,000.00 |
| Jun 30, 2023 | 144,000.00 |
| Mar 31, 2023 | 93,000.00 |
| Mar 31, 2023 | 93,000.00 |
| Dec 31, 2022 | 86,000.00 |
| Dec 31, 2022 | 86,000.00 |
| Sep 30, 2022 | 252,000.00 |
| Sep 30, 2022 | 252,000.00 |
| Jun 30, 2022 | 336,000.00 |
| Jun 30, 2022 | 336,000.00 |
| Mar 31, 2022 | 358,000.00 |
| Mar 31, 2022 | 358,000.00 |
| Dec 31, 2021 | 683,000.00 |
| Dec 31, 2021 | 683,000.00 |
| Sep 30, 2021 | 103,000.00 |
| Sep 30, 2021 | 103,000.00 |
| Jun 30, 2021 | 495,000.00 |
| Jun 30, 2021 | 495,000.00 |
| Mar 31, 2021 | 569,000.00 |
| Mar 31, 2021 | 569,000.00 |
| Dec 31, 2020 | 470,000.00 |
| Dec 31, 2020 | 470,000.00 |
| Sep 30, 2020 | 664,000.00 |
| Sep 30, 2020 | 664,000.00 |
| Jun 30, 2020 | 393,000.00 |
| Jun 30, 2020 | 393,000.00 |
| Mar 31, 2020 | 75,892.00 |
| Mar 31, 2020 | 75,892.00 |
| Dec 31, 2019 | 119,445.00 |
| Dec 31, 2019 | 119,445.00 |
| Sep 30, 2019 | 294,600.00 |
| Sep 30, 2019 | 294,600.00 |
| Jun 30, 2019 | 128,778.00 |
| Jun 30, 2019 | 128,778.00 |
| Mar 31, 2019 | 337,966.00 |
| Mar 31, 2019 | 337,966.00 |
| Dec 31, 2018 | 63,809.00 |
| Dec 31, 2018 | 63,809.00 |
| Sep 30, 2018 | 134,695.00 |
| Sep 30, 2018 | 134,695.00 |
| Jun 30, 2018 | 196,742.00 |
| Jun 30, 2018 | 196,742.00 |
| Mar 31, 2018 | 238,835.00 |
| Mar 31, 2018 | 238,835.00 |
| Dec 31, 2017 | 265,821.00 |
| Dec 31, 2017 | 265,821.00 |
| Sep 30, 2017 | 329,755.00 |
| Sep 30, 2017 | 329,755.00 |
| Jun 30, 2017 | 651,949.00 |
| Jun 30, 2017 | 651,949.00 |
| Mar 31, 2017 | 522,439.00 |
| Mar 31, 2017 | 522,439.00 |
| Dec 31, 2016 | 578,766.00 |
| Dec 31, 2016 | 578,766.00 |
| Sep 30, 2016 | 578,820.00 |
| Sep 30, 2016 | 578,820.00 |
| Jun 30, 2016 | 817,067.00 |
| Jun 30, 2016 | 817,067.00 |
| Mar 31, 2016 | 1.47 Mn |
| Mar 31, 2016 | 1.47 Mn |
| Dec 31, 2015 | 830,318.00 |
| Dec 31, 2015 | 830,318.00 |
| Sep 30, 2015 | 805,232.00 |
| Sep 30, 2015 | 805,232.00 |
| Jun 30, 2015 | 625,959.00 |
| Jun 30, 2015 | 625,959.00 |
| Mar 31, 2015 | 689,857.00 |
| Mar 31, 2015 | 689,857.00 |
| Dec 31, 2014 | 681,101.00 |
| Dec 31, 2014 | 681,101.00 |
| Sep 30, 2014 | 656,947.00 |
| Sep 30, 2014 | 656,947.00 |
| Jun 30, 2014 | 541,026.00 |
| Jun 30, 2014 | 541,026.00 |
| Mar 31, 2014 | 2.44 Mn |
| Mar 31, 2014 | 2.44 Mn |
| Dec 31, 2013 | 250,661.00 |
| Dec 31, 2013 | 250,661.00 |
| Sep 30, 2013 | 1.01 Mn |
| Sep 30, 2013 | 1.01 Mn |
| Jun 30, 2013 | 596,576.00 |
| Jun 30, 2013 | 596,576.00 |
| Mar 31, 2013 | 476,711.00 |
| Mar 31, 2013 | 476,711.00 |
| Dec 31, 2012 | 423,153.00 |
| Dec 31, 2012 | 423,153.00 |
| Sep 30, 2012 | 486,700.00 |
| Sep 30, 2012 | 486,700.00 |
| Jun 30, 2012 | 330,713.00 |
| Jun 30, 2012 | 330,713.00 |
| Mar 31, 2012 | 370,279.00 |
| Mar 31, 2012 | 370,279.00 |
| Dec 31, 2011 | 458,401.00 |
| Dec 31, 2011 | 458,401.00 |
| Sep 30, 2011 | 667,624.00 |
| Sep 30, 2011 | 667,624.00 |
| Jun 30, 2011 | 1.06 Mn |
| Jun 30, 2011 | 1.06 Mn |
| Mar 31, 2011 | 1.15 Mn |
| Mar 31, 2011 | 1.15 Mn |
| Dec 31, 2010 | 1.30 Mn |
| Dec 31, 2010 | 1.30 Mn |
| Sep 30, 2010 | 1.31 Mn |
| Sep 30, 2010 | 1.31 Mn |